linjc16/ctgov huggingface dataset:
Evaluation of Nutritional Habits of University Students

Study Overview
=================
Brief Summary
-----------------
This cross- sectional, single-center study was conducted with the participation of 912 students studying at [removed for blind peer review] Faculty of Health Sciences, Faculty of Engineering and Natural Sciences, Faculty of Educational Sciences, Faculty of Social Sciences, Faculty of Law and Medicine. The sample size was calculated to be a minimum of 379 with 95% confidence over the total number of students, 5301. The study was carried out between October 2020 and December 2020. The compliance of the study with the ethical rules was evaluated by the Istanbul Medeniyet University Social and Human Sciences Research and Publication Ethics Committee at its meeting dated 27.10.2020 and approved with the decision numbered 2020/39. At the beginning of the study, verbal and written consent was obtained from the individuals and a questionnaire containing 29 questions was distributed by the researchers. The questionnaire form consists of three parts. The first part includes 10 questions to determine the demographic characteristics of the participants, the second part includes 17 questions to determine their eating habits, and the third part includes 2 questions to evaluate the status of following the news about nutrition and heart health and whether they find the public service ads on this subject sufficient.

Official Title
-----------------
A Cross-sectional Study on the Evaluation of Nutritional Habits of Students at Istanbul Medeniyet University.

Conditions
-----------------
Eating Habit, Health Knowledge, Attitudes, Practice

Intervention / Treatment
-----------------
* Other: Determination of Eating habits


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteering to participate in the research Istanbul Medeniyet University students between the ages of 18-25 Exclusion Criteria: Individuals who did not volunteer to participate in the study Adults over 25 All university students studying outside of Istanbul Medeniyet University Elderly individuals Children under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Determination of Eating habits|Questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reaching the targeted participant | Participants will be surveyed and evaluated with data obtained using appropriate statistical methods. | One month |
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Study Overview
=================
Brief Summary
-----------------
This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.

Detailed Description
-----------------
Each patient received a sham injection in one eye and active treatment in the other eye. The eye receiving active treatment was selected based on a randomization schedule.

Official Title
-----------------
A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD

Conditions
-----------------
Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Fluocinolone Acetonide
* Drug: Fluocinolone Acetonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis bilateral GA secondary to AMD of ≥ 0.5 and ≤ 7 MPS disc areas Males and non-pregnant females 55 years old or older Exclusion Criteria: GA secondary to any condition other than AMD in either eye History of or current CNV in either eye or the need for anti-angiogenic therapy Glaucoma or ocular hypertension (IOP > 21 mmHg OR concurrent therapy at screening with IOP-lowering agents) in either eye Treatment with intravitreal, subtenon, or periocular steroid within 6 months prior to enrollment in either eye Any change in systemic steroid therapy within 3 months of screening History of vitrectomy in either eye Any ocular surgery within 12 weeks of screening in either eye

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A, 2, I 0.2 µg/Day + Sham<br>0.2 µg/Day | Drug: Fluocinolone Acetonide<br>* 0.2 µg/Day in study eye + Sham in fellow eye<br>|
| Experimental: A, 2, II 0.5 µg/Day + Sham<br>0.5 µg/Day | Drug: Fluocinolone Acetonide<br>* 0.5 µg/Day in study eye +Sham in fellow eye<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Size of Geographic Atrophy |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, Age-Related Macular Degeneration, Geographic Atrophy, GA
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis.

Detailed Description
-----------------
Human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) Human Herpes virus6 (HHV-6)

Conditions
-----------------
Cytomegalovirus, Epstein-Barr Virus Infections, Herpesvirus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with peridontitis Exclusion Criteria: Previous periodontal treatment in last 3 month Toothbrushing disability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Prevelance Rate of the EBV, HCMV, HHV-6 in saliva | Check the EBV, HCMV, HHV-6 in saliva by PCR | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change outcomes EBV, HCMV, HHV-6 in saliva before and after toothbrushing | Check the EBV, HCMV, HHV-6 in saliva by RC-PCR before and after toothbrushing | 1 year |
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal disorders.

Official Title
-----------------
Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Letrozole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women receiving anastrozole adjuvant therapy for hormone receptor positive breast cancer who want to interrupt the treatment because of severe rheumatologic adverse events Polymorphonuclear neutrophils (PNN) ≥ 1200/mm3, platelets ≥ 100000/mm3, hemoglobin (Hb) ≥ 10 g/dL Bilirubin ≤ 30 μmol, SGOT/SGPT < 3N Fully signed informed consent Exclusion Criteria: Pain due to bone fracture Metastatic disease Hormone therapy other than anastrozole Incapacitating or uncontrolled concomitant disease that could hamper patient's quality of life Hypersensitivity to letrozole or its components Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Letrozole<br>to evaluate the rheumatological tolerability of Femara | Drug: Letrozole<br> <br> * Other names: Femara;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day |  | at 1, 3 and 6 months of letrozole treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the causes of discontinuation |  | at 1, 3 and 6 months of letrozole treatment | 
| To determine how long letrozole treatment is maintained |  | at 1, 3 and 6 months of letrozole treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Letrozole, breast cancer, critical musculoskeletal, postmenopausal, rheumatologic tolerance
In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate and compare the images obtained from coronary imaging catheters used in the treatment of coronary blockages both in a clinical setting with patients and in models.

Official Title
-----------------
Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Infraredx Test Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years of age Scheduled for a coronary angiogram at the Royal Adelaide Hospital. Women must be non-lactating or not of childbearing potential (1 year post menopausal or surgically sterilized [total hysterectomy, bilateral tubal ligation, bilateral oophorectomy]). Target artery must be >2 mm to accommodate the IVUS catheter. IVUS must be clinically indicated or indeterminate angiographic lesion in the artery (40%-70% angiographic stenosis) Exclusion Criteria: Cardiogenic shock Contraindications to intracoronary nitroglycerin (hypertrophic obstructive cardiomyopathy; cerebral hemorrhage, head trauma; concomitant sildenafil, tadalafil or vardenafil use) Known coronary artery spasm Significant bleeding risk (i.e. previous hemorrhagic stroke, active peptic ulcer disease) Bleeding diathesis Significant renal impairment (patients will be excluded if their calculated creatinine clearance is < 30 mL/min)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Eagle Eye Platinum<br>Eagle Eye Platinum Catheter as the comparator. | Device: Infraredx Test Catheter<br> <br> |
| Active Comparator: Revolution<br>Revolution Catheter as the comparator | Device: Infraredx Test Catheter<br> <br> |
| Active Comparator: TVC Insight 40MHz<br>TVC Insight as comparative catheter. | Device: Infraredx Test Catheter<br> <br> |
| Active Comparator: Atlantis Pro<br>Atlantis Pro catheter as comparator | Device: Infraredx Test Catheter<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clarity of Image and ease of interpretation as measured by physician survey |  | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of diameters and areas using ultrasound imaging from a standard test fixture(model) and test catheters |  | Day 0 |
Role of the Toxic Metal Cadmium in the Mechanism Producing Infertility With a Varicocele

Study Overview
=================
Brief Summary
-----------------
Varicose veins in the scrotum (varicocele) are responsible for >20% of male infertility in the US. Varicocele are associated with decreased sperm number and markedly reduced sperm fertilizing ability. Surgical repair or removal of varicocele restores fertility in only 1/3 of cases. The goal of this study is to identify markers that predict the outcome of variocele correction. This would offer considerable health cost savings. Based on preliminary findings, we will obtain testis biopsies and semen specimens from infertile men with varicocele and prospectively examining the levels of cadmium, a toxic metal, and expression of genes required for normal sperm function. The semen and biopsies will be obtained during clinically dictated procedures. Cadmium and gene expression will be compared with response to varicocele repair (i.e., increased sperm production; pregnancy).

Official Title
-----------------
Increased Testicular Cd2+ & Infertility With Varicocele ( a Varicose Vein in the Scrotum)

Conditions
-----------------
Varicocele, Male Infertility, Hypospermatogenesis, Non-Obstructive Azoospermia

Intervention / Treatment
-----------------
* Procedure: Varicocele repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Healthy male with varicocele (grades 2 [palpable] or 3 [visible, palpable]) and no other diagnosed cause for infertility Non-smoker Actively desiring children but never having initiated a pregnancy Female partner having no unresolved fertility issues

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Varicocele repair|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Varicocele, environmental toxins, male infertility, cadmium
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Study Overview
=================
Brief Summary
-----------------
The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Official Title
-----------------
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Conditions
-----------------
Scleroderma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years Able to give informed consent. Diagnosed with scleroderma or with positive autoantibodies Exclusion Criteria: < 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Rodnan Skin Score |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medsger Severity Score |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
scleroderma, biorepository
Aromatherapy Protocol for Pain Reduction in Hospice Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to introduce aromatherapy with current pain medication protocols to see if it improves patient satisfaction and reduces pain in hospice care patients.

Official Title
-----------------
Aromatherapy Protocol for Pain Reduction in Hospice Patients

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Other: Aromatherapy treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: currently on hospice at Seasons Assisted Living Exclusion Criteria: pain level not 3/10 or higher

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br> | Other: Aromatherapy treatment<br>* 60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction as assessed by the score on the Patient Satisfaction survey | This survey has 4 questions and each is scored from 1(strongly disagree) to 5(strongly agree) for a maximum score of 20, a higher score indicating more satisfaction | end of study (7 days after baseline) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain as assessed by the score on the Wong Baker Face Scale (WBFPS) scale | This is scored from 0(no hurt) to 10(hurts the worst) a higher number indicating more pain | Baseline, 2 hours after every aromatherapy administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hospice care
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).

Detailed Description
-----------------
The purpose of this study is to: assess the safety and efficacy of multiple dose levels of INS37217 compared to placebo over 28 days in subjects with mild to moderate CF lung disease; explore evidence of activity of INS37217 and placebo administered via PARI LC STAR nebulizer; identify dose(s) that will be studied in subsequent trials.

Official Title
-----------------
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: denufosol tetrasodium (INS37217)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of CF FEV1 greater than or equal to 75% of predicted normal for age, gender, and height oxyhemoglobin saturation greater than or equal to 90% clinically stable Exclusion Criteria: abnormal renal or liver function clinically significant findings atypical for moderate cystic fibrosis

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: denufosol tetrasodium (INS37217)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung function |  |  | 
| respiratory symptoms |  |  | 
| sputum weight |  |  | 
| pulmonary exacerbations |  |  | 
| measures of lung characteristics |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety measures |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cystic fibrosis
Diagnosis of Active Tuberculosis by ELISPOT

Study Overview
=================
Brief Summary
-----------------
Recent studies revealed that the ex vivo enzyme-linked immunospot (ELISPOT) assay for gamma interferon is a specific method for contact tracing of Mycobacterium tuberculosis infection. However, its use in endemic area and bacillus Calmette-Guérin (BCG)-vaccinated hosts has not been proved. We hypothesize that the TB-ELISPOT assay can be a rapid and accurate diagnostic tool for active tuberculosis in clinical suspects in Taiwan.

Official Title
-----------------
Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who present with fever or respiratory symptoms (cough, dyspnea, or hemoptysis) lasting for ≥ 2 weeks and have compatible radiographic findings were considered clinical suspects of TB. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tuberculosis, TB-ELISPOT, active tuberculosis latent infection interferon